Related Experiment Videos
[PTCA for acute coronary syndrome]
M Nobuyoshi1, H Yokoi, Y Nakagawa
1Department of Cardiology, Kokura Memorial Hospital.
Insights
Intravenous thrombolytic therapy improves acute myocardial infarction (MI) outcomes but has limitations. Percutaneous coronary intervention (PCI) strategies, including stenting, offer improved reperfusion and are recommended when available.
Area of Science:
- Cardiology
- Interventional Cardiology
Context:
- Acute myocardial infarction (MI) management has been transformed by thrombolytic therapy.
- Despite benefits, limitations like patient eligibility and reperfusion rates persist.
Purpose:
- To review current reperfusion strategies for acute MI.
- To compare thrombolytic therapy with percutaneous coronary intervention (PCI) approaches.
- To evaluate the role of coronary stenting in acute MI.
Summary:
- Intravenous thrombolytic therapy offers survival benefits but faces challenges in patient selection, reperfusion success, and complication rates.
- Percutaneous coronary intervention (PCI) strategies, including primary PCI, rescue PCI, and delayed PCI, have emerged to address thrombolysis deficiencies.
- Primary PCI is optimal when skilled teams and facilities are available; otherwise, thrombolysis is indicated for eligible patients.
- Coronary stenting shows promise for acute MI, with ongoing trials to validate its efficacy, particularly for provisional stenting.
Impact:
- Optimizing reperfusion strategies can improve patient survival and left ventricular (LV) function in acute MI.
- The findings guide clinical decisions on the most effective reperfusion method based on resource availability and patient factors.
- Further research, including randomized trials, is crucial to establish the definitive role of coronary stenting in acute MI management.
Abstract:
The use of intravenous thrombolytic therapy have revolutionized the medical management of acute MI, prolonging survival and preserving LV function. Yet, despite these important beneficial effects, many deficiencies exist, such as the fewer lytic eligible patients, the low rate of complete reperfusion and high incidence of recurrent Ischemia and intracranial hemorrhage. To improve on these deficiencies, several PTCA strategies for acute MI have emerged, including primary PTCA, rescue PTCA, immediate PTCA, and delayed PTCA. If skilled intervention-list and cath lab team are available, the optimal reperfusion strategy is primary PTCA. If a cath lab is not available and the patient is eligible for thrombolysis, intravenous thrombolytic therapy should be administered. Nevertheless, PTCA still has significant limitations, including complex lesion morphology and restenosis. Preliminary experience support the feasibility and safety of coronary stenting in the setting of acute MI. A randomized trial using the heparin-coated Palmaz-Schatz stent for primary stenting in MI is ongoing. Until a randomized trial data are available, we recommend stenting for provisional stenting.